Skip to content

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again

      1. Home/
      2. Transparency/
      3. The 2020 Janssen U.S. Transparency Report

      The 2020 Janssen U.S. Transparency Report

      Building a healthier future for all

      Share Article
      Share to

      In our 2020 U.S. Transparency Report, we reported a 5.7% average net price decline for our medicines, marking the fourth consecutive year of such reductions. We provided $29.4 billion in rebates, discounts and fees to various healthcare entities, including private payers, government programs and providers, while investing $9.6 billion globally in research and development to discover and develop new medicines and vaccines.

      Read the executive summary below, or view the full report here.

      2020-executive-summary.png

      All figures according to Johnson & Johnson internal financial accounting. Figures have been rounded.